PortfoliosLab logoPortfoliosLab logo
PVLA vs. BRO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PVLA vs. BRO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Palvella Therapeutics, Inc (PVLA) and Brown & Brown, Inc. (BRO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PVLA achieves a 39.51% return, which is significantly higher than BRO's -12.71% return.


PVLA

1D
0.88%
1M
34.21%
6M
45.32%
YTD
39.51%
1Y
451.89%
3Y*
5Y*
10Y*

BRO

1D
2.29%
1M
15.37%
6M
-12.61%
YTD
-12.71%
1Y
-34.59%
3Y*
0.95%
5Y*
6.31%
10Y*
15.41%
*Multi-year figures are annualized to reflect compound growth (CAGR)

PVLA vs. BRO - Yearly Performance Comparison


2026 (YTD)20252024
PVLA
Palvella Therapeutics, Inc
39.51%772.25%-8.27%
BRO
Brown & Brown, Inc.
-12.71%-21.37%-2.08%

Correlation

The correlation between PVLA and BRO is -0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

-0.06

Correlation (All Time)
Calculated using the full available price history since Dec 16, 2024

0.01

Fundamentals

Market Cap

PVLA:

$1.73B

BRO:

$23.46B

EPS

PVLA:

-$3.74

BRO:

$5.13

Total Revenue (TTM)

PVLA:

$0.00

BRO:

$6.43B

Gross Profit (TTM)

PVLA:

$0.00

BRO:

$3.82B

EBITDA (TTM)

PVLA:

-$14.75M

BRO:

$1.51B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PVLA vs. BRO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PVLA
PVLA Risk / Return Rank: 9898
Overall Rank
PVLA Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
PVLA Sortino Ratio Rank: 9898
Sortino Ratio Rank
PVLA Omega Ratio Rank: 9696
Omega Ratio Rank
PVLA Calmar Ratio Rank: 9999
Calmar Ratio Rank
PVLA Martin Ratio Rank: 9999
Martin Ratio Rank

BRO
BRO Risk / Return Rank: 1010
Overall Rank
BRO Sharpe Ratio Rank: 33
Sharpe Ratio Rank
BRO Sortino Ratio Rank: 66
Sortino Ratio Rank
BRO Omega Ratio Rank: 66
Omega Ratio Rank
BRO Calmar Ratio Rank: 1818
Calmar Ratio Rank
BRO Martin Ratio Rank: 1919
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PVLA vs. BRO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Palvella Therapeutics, Inc (PVLA) and Brown & Brown, Inc. (BRO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PVLABRODifference
Sharpe ratioReturn per unit of total volatility

+6.69

Sortino ratioReturn per unit of downside risk

+6.08

Omega ratioGain probability vs. loss probability

1.54

0.80

+0.74

Calmar ratioReturn relative to maximum drawdown

14.65

-0.71

+15.35

Martin ratioReturn relative to average drawdown

32.81

-1.13

+33.94

PVLA vs. BRO - Sharpe Ratio Comparison

The current PVLA Sharpe Ratio is 5.53, which is higher than the BRO Sharpe Ratio of -1.16. The chart below compares the historical Sharpe Ratios of PVLA and BRO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PVLA vs. BRO - Drawdown Comparison

The maximum PVLA drawdown since its inception was -31.48%, smaller than the maximum BRO drawdown of -55.85%. Use the drawdown chart below to compare losses from any high point for PVLA and BRO.


Loading charts...

Drawdown Indicators


PVLABRODifference

Max Drawdown

Largest peak-to-trough decline

-31.48%

-55.85%

+24.37%

Max Drawdown (1Y)

Largest decline over 1 year

-31.11%

-49.19%

+18.08%

Max Drawdown (3Y)

Largest decline over 3 years

-55.85%

Max Drawdown (5Y)

Largest decline over 5 years

-55.85%

Max Drawdown (10Y)

Largest decline over 10 years

-55.85%

Current Drawdown

Current decline from peak

-5.69%

-43.81%

+38.12%

Average Drawdown

Average peak-to-trough decline

-10.98%

-13.61%

+2.63%

Ulcer Index

Depth and duration of drawdowns from previous peaks

13.86%

30.59%

-16.73%

Volatility

PVLA vs. BRO - Volatility Comparison

Palvella Therapeutics, Inc (PVLA) has a higher volatility of 22.21% compared to Brown & Brown, Inc. (BRO) at 10.22%. This indicates that PVLA's price experiences larger fluctuations and is considered to be riskier than BRO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PVLABRODifference

Volatility (1M)

Calculated over the trailing 1-month period

22.21%

10.22%

+11.99%

Volatility (6M)

Calculated over the trailing 6-month period

60.65%

23.48%

+37.17%

Volatility (1Y)

Calculated over the trailing 1-year period

82.51%

30.09%

+52.42%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

82.25%

25.21%

+57.04%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

82.25%

23.83%

+58.42%

Dividends

PVLA vs. BRO - Dividend Comparison

PVLA has not paid dividends to shareholders, while BRO's dividend yield for the trailing twelve months is around 0.93%.


PositionTTM20252024202320222021202020192018201720162015
BRO
Brown & Brown, Inc.
0.93%0.77%0.53%0.67%0.74%0.54%0.73%0.82%1.11%1.08%1.12%1.41%
PVLA
Palvella Therapeutics, Inc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

PVLA vs. BRO - Financials Comparison

This section allows you to compare key financial metrics between Palvella Therapeutics, Inc and Brown & Brown, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00M1.00B1.50B2.00BOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober20260
1.90B
(PVLA) Total Revenue
(BRO) Total Revenue
Values in USD except per share items

Frequently Asked Questions


PVLA and BRO have a correlation of -0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

PVLA has higher volatility (22.21%) compared to BRO (10.22%). In terms of maximum drawdown, PVLA dropped -31.48% vs BRO's -55.85%.

PVLA currently has the higher Sharpe Ratio (5.53 vs -1.16), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PVLA and BRO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer